<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1646-2122</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Ortopedia e Traumatologia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Port. Ortop. Traum.]]></abbrev-journal-title>
<issn>1646-2122</issn>
<publisher>
<publisher-name><![CDATA[Sociedade Portuguesa de Ortopedia e Traumatologia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1646-21222014000100003</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Pé de Charcot: Uma visão actual da neuroartropatia de Charcot]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pinheiro]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Centro Hospitalar do Porto Serviço de Angiologia e Cirurgia Vascular Consulta de Pé Diabético]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2014</year>
</pub-date>
<volume>22</volume>
<numero>1</numero>
<fpage>24</fpage>
<lpage>33</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S1646-21222014000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S1646-21222014000100003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S1646-21222014000100003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[A neuroartropatia de Charcot (NAC) é uma deformidade osteoarticular do pé neuropático causada predominantemente pela Diabetes. O atraso no diagnóstico e tratamento da NAC pode conduzir à ulceração e amputação do pé, daí a importância de um diagnóstico e tratamento precoce. O mecanismo exato da patogénese da NAC ainda não está estabelecido, considerando-se que quer a teoria neurotraumática quer a neurovascular poderão ter um papel importante. O diagnóstico da NAC aguda é predominantemente clínico, apresentando-se o pé afectado com hiperemia, edema e elevação da temperatura. Na fase crónica o pé não apresenta sinais inflamatórios mas mantém o edema e apresenta várias deformidades resultantes do atingimento osteoarticular e muscular. Embora vários autores tenham apresentado diferentes sistemas de classificação com alguma importância clínica, estes não possuem valor prognóstico. A NAC é uma neuroartropatia com consequências individuais e sociais importantes, que estando predominantemente associada à epidemia da Diabetes, merece especial atenção a fim de diagnosticarmos e tratarmos precocemente esta complicação decorrente deste grave problema de saúde pública. O objectivo deste trabalho centrou-se na revisão bibliográfica da NAC a fim de adquirir os conhecimentos mais recentes nas várias dimensões desta patologia, nomeadamente epidemiologia, patogénese, apresentação clínica, diagnóstico e formas de classificação. Foi realizada uma pesquisa na pubmed/medline com as palavras “Charcot foot” e “Charcot neuroarthropathy”, selecionando sobretudo artigos publicados nos últimos 15 anos, incluindo artigos originais e de revisão.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[The Charcot neuroarthropathy (CNA) is a osteoarticular neuropathic foot deformity mainly caused by diabetes. The delay in diagnosis and treatment of CNA can lead to ulceration and amputation of the foot, hence the importance of early diagnosis and treatment. The exact mechanism of its pathogenesis is not yet established, but both theories, neurovascular and neurotraumatic, may play an important role. The diagnosis of acute CNA is predominantly clinical presenting the affected foot hyperemia, swelling and elevated temperature. In the chronic phase the foot shows no signs of inflammation but keeps swelling and has several deformities. The CNA can be classified according to different classification systems with some clinical importance, but not prognostic. The CNA is a neuroarthropathy with important individual and social consequences, that being predominantly associated with diabetes, deserves special attention in order to diagnose and treat this complication early since this serious public health problem. The aim of this article focused on the literature review of CNA in order to acquire the latest knowledge in the various dimensions of this disease, including epidemiology, pathogenesis, clinical presentation, diagnosis and classification forms. Research was carried out in pubmed / medline with the words “Charcot foot" and "Charcot neuroarthropathy”, selecting particular articles published in the last 15 years, including original and review articles.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Pé de Charcot]]></kwd>
<kwd lng="pt"><![CDATA[neuroartropatia de Charcot]]></kwd>
<kwd lng="pt"><![CDATA[epidemiologia]]></kwd>
<kwd lng="pt"><![CDATA[patogénese]]></kwd>
<kwd lng="pt"><![CDATA[apresentação clínica]]></kwd>
<kwd lng="pt"><![CDATA[diagnóstico]]></kwd>
<kwd lng="pt"><![CDATA[classificação]]></kwd>
<kwd lng="en"><![CDATA[Charcot foot]]></kwd>
<kwd lng="en"><![CDATA[Charcot neuroarthropathy]]></kwd>
<kwd lng="en"><![CDATA[epidemiology]]></kwd>
<kwd lng="en"><![CDATA[pathogenesis]]></kwd>
<kwd lng="en"><![CDATA[clinical presentation]]></kwd>
<kwd lng="en"><![CDATA[diagnosis]]></kwd>
<kwd lng="en"><![CDATA[classification]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><b><font face="Verdana" size="2">ARTIGO DE REVISÃO</font></b></p>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="4">Pé de Charcot - Uma visão actual da neuroartropatia de Charcot</font></b></p>    <p>&nbsp;</p>    <p><font face="Verdana" size="2"><b>Ana Pinheiro<sup>I</sup></b></font></p>    <p><font face="Verdana" size="2">I. Consulta de Pé Diabético. Serviço de Angiologia e Cirurgia Vascular. Centro Hospitalar do Porto.<br /></font></p>    <p>&nbsp;</p>    <p><font face="Verdana" size="2"><a name="topc"></a><a href="#c">Endereço para correspondência</a></font></p>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">RESUMO</font></b></p><font face="verdana" size="2">    ]]></body>
<body><![CDATA[<p>A neuroartropatia de Charcot (NAC) &eacute; uma deformidade osteoarticular do p&eacute; neurop&aacute;tico causada predominantemente pela Diabetes. O atraso no diagn&oacute;stico e tratamento da NAC pode conduzir &agrave; ulcera&ccedil;&atilde;o e amputa&ccedil;&atilde;o do p&eacute;, da&iacute; a import&acirc;ncia de um diagn&oacute;stico e tratamento precoce.</p>     <p>O mecanismo exato da patog&eacute;nese da NAC ainda n&atilde;o est&aacute; estabelecido, considerando-se que quer a teoria neurotraum&aacute;tica quer a neurovascular poder&atilde;o ter um papel importante.</p>     <p>O diagn&oacute;stico da NAC aguda &eacute; predominantemente cl&iacute;nico, apresentando-se o p&eacute; afectado com hiperemia, edema e eleva&ccedil;&atilde;o da temperatura. Na fase cr&oacute;nica o p&eacute; n&atilde;o apresenta sinais inflamat&oacute;rios mas mant&eacute;m o edema e apresenta v&aacute;rias deformidades resultantes do atingimento osteoarticular e muscular.</p>     <p>Embora v&aacute;rios autores tenham apresentado diferentes sistemas de classifica&ccedil;&atilde;o com alguma import&acirc;ncia cl&iacute;nica, estes n&atilde;o possuem valor progn&oacute;stico.</p>     <p>A NAC &eacute; uma neuroartropatia com consequ&ecirc;ncias individuais e sociais importantes, que estando predominantemente associada &agrave; epidemia da Diabetes, merece especial aten&ccedil;&atilde;o a fim de diagnosticarmos e tratarmos precocemente esta complica&ccedil;&atilde;o decorrente deste grave problema de sa&uacute;de p&uacute;blica.</p>     <p>O objectivo deste trabalho centrou-se na revis&atilde;o bibliogr&aacute;fica da NAC a fim de adquirir os conhecimentos mais recentes nas v&aacute;rias dimens&otilde;es desta patologia, nomeadamente epidemiologia, patog&eacute;nese, apresenta&ccedil;&atilde;o cl&iacute;nica, diagn&oacute;stico e formas de classifica&ccedil;&atilde;o.</p>     <p>Foi realizada uma pesquisa na pubmed/medline com as palavras &ldquo;Charcot foot&rdquo; e &ldquo;Charcot neuroarthropathy&rdquo;, selecionando sobretudo artigos publicados nos &uacute;ltimos 15 anos, incluindo artigos originais e de revis&atilde;o.</p></font>    <p><font face="verdana" size="2"><b>Palavras chave</b>: Pé de Charcot, neuroartropatia de Charcot, epidemiologia, patogénese, apresentação clínica, diagnóstico, classificação. </font></p>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">ABSTRACT</font></b></p><font face="verdana" size="2">    ]]></body>
<body><![CDATA[<p>The Charcot neuroarthropathy (CNA) is a osteoarticular neuropathic foot deformity mainly caused by diabetes. The delay in diagnosis and treatment of CNA can lead to ulceration and amputation of the foot, hence the importance of early diagnosis and treatment.</p>     <p>The exact mechanism of its pathogenesis is not yet established, but both theories, neurovascular and neurotraumatic, may play an important role.</p>     <p>The diagnosis of acute CNA is predominantly clinical presenting the affected foot hyperemia, swelling and elevated temperature. In the chronic phase the foot shows no signs of inflammation but keeps swelling and has several deformities.</p>     <p>The CNA can be classified according to different classification systems with some clinical importance, but not prognostic.</p>     <p>The CNA is a neuroarthropathy with important individual and social consequences, that being predominantly associated with diabetes, deserves special attention in order to diagnose and treat this complication early since this serious public health problem.</p>     <p>The aim of this article focused on the literature review of CNA in order to acquire the latest knowledge in the various dimensions of this disease, including epidemiology, pathogenesis, clinical presentation, diagnosis and classification forms.</p>     <p>Research was carried out in pubmed / medline with the words &ldquo;Charcot foot" and "Charcot neuroarthropathy&rdquo;, selecting particular articles published in the last 15 years, including original and review articles.</p></font>    <p><font face="verdana" size="2"><b>Key words</b>: Charcot foot, Charcot neuroarthropathy, epidemiology, pathogenesis, clinical presentation, diagnosis, classification. </font></p>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">INTRODUÇÃO</font></b></p><font face="verdana" size="2">    ]]></body>
<body><![CDATA[<p>A neuroartropatia de Charcot (NAC) &eacute; uma deformidade &oacute;ssea e articular do p&eacute; neurop&aacute;tico, em que a arquitectura e a organiza&ccedil;&atilde;o estrutural dos ossos est&atilde;o alteradas, apresentando altera&ccedil;&otilde;es radiogr&aacute;ficas caracterizadas por destrui&ccedil;&atilde;o e remodela&ccedil;&atilde;o &oacute;ssea, destrui&ccedil;&atilde;o articular, subluxa&ccedil;&atilde;o e luxa&ccedil;&atilde;o1-4.</p>
    <p>Apesar de reconhecer que foi Mitchell o primeiro m&eacute;dico a descrever a destrui&ccedil;&atilde;o osteoarticular associada &agrave; disfun&ccedil;&atilde;o neurol&oacute;gica, foi Charcot que em 1868, fez a primeira descri&ccedil;&atilde;o histopatol&oacute;gica detalhada das altera&ccedil;&otilde;es presentes na Tabes Dorsalis. Em 1881, Paget, num congresso m&eacute;dico internacional em Londres, sugeriu a defini&ccedil;&atilde;o doen&ccedil;a de Charcot para esta entidade patol&oacute;gica detentora de v&aacute;rias defini&ccedil;&otilde;es<sup>4, 5, 6, 7</sup>.</p>
    <p>Apesar da Diabetes ser actualmente a principal causa de NAC em todo o mundo, s&oacute; em 1936, esta patologia foi pela primeira vez descrita como uma complica&ccedil;&atilde;o da Diabetes<sup>1,2,5,6</sup>.</p>
    <p>Embora seja reconhecida h&aacute; mais de 300 anos, a NAC continua a ser uma entidade complexa e dif&iacute;cil no que toca ao seu diagn&oacute;stico e tratamento. Os profissionais de sa&uacute;de devem estar, por isso, atentos a esta patologia dada a tend&ecirc;ncia crescente da Diabetes e das suas complica&ccedil;&otilde;es5.</p>
    <p>O objectivo deste trabalho centrou-se na revis&atilde;o bibliogr&aacute;fica da NAC a fim de reunir os conhecimentos mais recentes nas v&aacute;rias dimens&otilde;es desta patologia, nomeadamente epidemiologia, patog&eacute;nese, apresenta&ccedil;&atilde;o cl&iacute;nica, diagn&oacute;stico e formas de classifica&ccedil;&atilde;o.</p></font>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">EPIDEMIOLOGIA</font></b></p><font face="verdana" size="2">    <p>A NAC apresenta-se frequentemente sem aviso e pode rapidamente deteriorar-se numa deformidade grave e irrevers&iacute;vel do p&eacute; que pode conduzir &agrave; ulcera&ccedil;&atilde;o e amputa&ccedil;&atilde;o<sup>4,5</sup>.</p>
    <p>A incid&ecirc;ncia e preval&ecirc;ncia da NAC permanecem desconhecidas devido &agrave; dificuldade e ao atraso no diagn&oacute;stico decorrentes da inexist&ecirc;ncia de crit&eacute;rios de diagn&oacute;stico cl&iacute;nicos e radiol&oacute;gicos estandardizados6. No entanto, a preval&ecirc;ncia relatada oscila entre 0,1 a 0,4<sup>6,8</sup>.</p>
    <p>A incid&ecirc;ncia desta patologia tem aumentado devido, em parte, &agrave; melhoria dos m&eacute;todos de imagem e ao menor n&uacute;mero de amputa&ccedil;&otilde;es9.</p>
    ]]></body>
<body><![CDATA[<p>A NAC &eacute; uma complica&ccedil;&atilde;o complexa da Diabetes que est&aacute; presente em cerca de 0,8-8% dos diab&eacute;ticos e em 10% dos diab&eacute;ticos com neuropatia e altera&ccedil;&otilde;es radiogr&aacute;ficas associadas<sup>9,10</sup>.</p>
    <p>A incid&ecirc;ncia e preval&ecirc;ncia do P&eacute; de Charcot diferem entre pacientes diab&eacute;ticos tipo-l e tipo-ll. Pacientes com Diabetes tipo-l apresentam altera&ccedil;&otilde;es t&iacute;picas do P&eacute; de Charcot em idades mais jovens e t&ecirc;m maior predisposi&ccedil;&atilde;o para desenvolver a patologia que os diab&eacute;ticos tipo-ll11.</p>
    <p>Esta grave complica&ccedil;&atilde;o da Diabetes reduz a qualidade de vida e aumenta a morbilidade e mortalidade dos pacientes12.</p>
    <p>O P&eacute; de Charcot surge habitualmente na quinta ou sexta d&eacute;cada de vida, ap&oacute;s cerca de 10 anos do surgimento da Diabetes6.</p>
    <p>Apesar de actualmente a Diabetes ser a principal causa de NAC, esta pode surgir associada a h&aacute;bitos et&iacute;licos marcados, siringomielia, neuros&iacute;filis, lepra e outras patologias neurol&oacute;gicas<sup>4, 6, 9,12, 13</sup>.</p>
    <p>A NAC atinge igualmente ambos os sexos e apresenta-se habitualmente de forma assim&eacute;trica9.</p></font>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">PATOGÉNESE</font></b></p><font face="verdana" size="2">    <p>O mecanismo exato da patog&eacute;nese da NAC ainda n&atilde;o est&aacute; estabelecido14.</p>
    <p>Duas teorias tentam explicar a sua patog&eacute;nese: a teoria Neurotraum&aacute;tica (Alem&atilde;) e a Neurovascular (Francesa). Considera-se, no presente, que ambas as teorias poder&atilde;o ter um papel importante na patog&eacute;nese da NAC<sup>1,4,5,6</sup>.</p>
    ]]></body>
<body><![CDATA[<p>Segundo a teoria neurotraum&aacute;tica a destrui&ccedil;&atilde;o &oacute;ssea deve-se &agrave; perda sensitiva associada aos repetitivos traumas mec&acirc;nicos do p&eacute;. O trauma impercept&iacute;vel combinado com a sustenta&ccedil;&atilde;o do peso no membro afectado causar&aacute; fracturas e destrui&ccedil;&atilde;o articular caracter&iacute;sticas desta patologia6.</p>
    <p>Por outro lado, na teoria neurovascular, a destrui&ccedil;&atilde;o articular ser&aacute; causada por um reflexo vascular secund&aacute;rio a uma desregula&ccedil;&atilde;o neurol&oacute;gica aut&oacute;noma (simpatectomia) que vai causar hiperemia e osteopenia periarticular atrav&eacute;s da activa&ccedil;&atilde;o de osteoclastos, o que facilita a ocorr&ecirc;ncia de fracturas com o trauma<sup>6, 15, 16</sup>.</p>
    <p>A neuropatia auton&oacute;mica resulta numa osteopenia que associada &agrave; perda de sensa&ccedil;&atilde;o protectora causada pela neuropatia sensitiva, predisp&otilde;e &agrave; destrui&ccedil;&atilde;o &oacute;ssea ocorrida durante a marcha, pois o paciente n&atilde;o se apercebe do trauma. A NAC resulta assim deste ciclo vicioso em que o paciente continua a caminhar no p&eacute; doente permitindo o aparecimento de mais les&otilde;es<sup>16,17</sup>.</p>
    <p>De referir que a resultante disfun&ccedil;&atilde;o dos m&uacute;sculos intr&iacute;nsecos do p&eacute; origina sobrecarga em determinadas &aacute;reas, levando ao surgimento de microfracturas, laxidez dos ligamentos e &agrave; progress&atilde;o para a destrui&ccedil;&atilde;o &oacute;ssea<sup>16,17</sup>.</p>
    <p>Tamb&eacute;m as citoquinas pr&oacute;-inflamat&oacute;rias parecem ter um importante papel na patog&eacute;nese do P&eacute; de Charcot. A resposta inflamat&oacute;ria causada pelo trauma no p&eacute; originaria um desequil&iacute;brio na regula&ccedil;&atilde;o da citoquina RANK-L, respons&aacute;vel pela activa&ccedil;&atilde;o dos osteoclastos, originando osteopenia, oste&oacute;lise e mediocalcinose das art&eacute;rias do tornozelo<sup>5, 6,14,16-20</sup>. A <a href="/img/revistas/rpot/v22n1/22n1a03f1.jpg">figura 1</a> demonstra o mecanismo explicativo da patog&eacute;nese da NAC.</p>    
<p>&nbsp;</p>    <p>    <center><a href="/img/revistas/rpot/v22n1/22n1a03f1.jpg">Figura 1</a></center></p>    
<p>&nbsp;</p></font>    <p>&nbsp;</p>    ]]></body>
<body><![CDATA[<p><b><font face="Verdana" size="2">APRESENTAÇÃO CLÍNICA E DIAGNÓSTICO</font></b></p><font face="verdana" size="2">    <p>Clinicamente a artropatia de Charcot pode-se apresentar sob duas formas, a fase aguda e a fase cr&oacute;nica6.</p>
    <p>O diagn&oacute;stico da NAC aguda &eacute; predominantemente cl&iacute;nico e deve-se suspeitar desta entidade patol&oacute;gica na presen&ccedil;a de um p&eacute; com sinais sugestivos de inflama&ccedil;&atilde;o, na aus&ecirc;ncia de febre e de uma porta de entrada vis&iacute;vel, como feridas interdigitais ou &uacute;lceras plantares<sup>6,23,24</sup>.</p>
    <p>O P&eacute; de Charcot agudo apresenta-se com hiperemia, edema, eleva&ccedil;&atilde;o de temperatura superior a 2 graus quando comparado com o outro p&eacute;, pele muito seca e neuropatia sensitiva. A sensibilidade proprioceptiva e os reflexos est&atilde;o diminu&iacute;dos ou ausentes. A dor pode estar presente em graus vari&aacute;veis ou mesmo ausente, dependendo do grau de disfun&ccedil;&atilde;o nervosa. Os pulsos arteriais do p&eacute; atingido est&atilde;o mantidos ou mesmo aumentados decorrente da vasodilata&ccedil;&atilde;o perif&eacute;rica caracter&iacute;stica da NAC21-24.</p>
    <p>A apresenta&ccedil;&atilde;o aguda da NAC pode mimetizar uma crise de gota, TVP ou celulite, da&iacute; a import&acirc;ncia do doseamento de determinados par&acirc;metros serol&oacute;gicos, como a PCR e o &aacute;cido &uacute;rico, e da imagiologia na distin&ccedil;&atilde;o destas diferentes entidades patol&oacute;gicas<sup>6,7</sup>.</p>
    <p>O diagn&oacute;stico cl&iacute;nico da fase aguda &eacute; dif&iacute;cil e a radiografia muitas vezes n&atilde;o consegue identificar ou distinguir esta entidade de outras condi&ccedil;&otilde;es, falhando o diagn&oacute;stico de fratura e/ou luxa&ccedil;&atilde;o. Por sua vez, a cintigrafia &oacute;ssea com radiois&oacute;topo tecn&eacute;sio apresenta boa sensibilidade e baixa especificidade para esta patologia. &Eacute; de salientar, contudo, que apenas a resson&acirc;ncia magn&eacute;tica (RMN) &eacute; capaz de revelar, com maior pormenor, a natureza do dano e da inflama&ccedil;&atilde;o &oacute;ssea e dos tecidos moles adjacentes (edema da medula &oacute;ssea subcondral com ou sem microfracturas). A RMN &eacute;, assim, particularmente &uacute;til nos primeiros estadios da doen&ccedil;a, verificando-se uma correla&ccedil;&atilde;o significativa entre a intensidade do edema da medula &oacute;ssea e determinados par&acirc;metros cl&iacute;nicos, como o edema das partes moles e a dor<sup>6, 7, 25</sup>.</p>
    <p>O diagn&oacute;stico da NAC aguda &eacute;, portanto, baseado na hist&oacute;ria e no exame cl&iacute;nico mas deve ser confirmado atrav&eacute;s de m&eacute;todos de imagem. A Radiografia do p&eacute; deve ser o primeiro exame de imagem a ser realizado a fim de verificar a ocorr&ecirc;ncia de fraturas ou subluxa&ccedil;&otilde;es subtis. Quando apesar da suspei&ccedil;&atilde;o cl&iacute;nica, a Radiografia do p&eacute; &eacute; aparentemente normal, a RMN e a imagiologia nuclear podem, algumas vezes, confirmar o diagn&oacute;stico7.</p>
    <p>&Eacute; de real&ccedil;ar que o atraso no diagn&oacute;stico correto da NAC aguda apresenta consequ&ecirc;ncias graves, na medida em que o paciente ao continuar a fazer carga no p&eacute; afetado ir&aacute; aumentar a destrui&ccedil;&atilde;o &oacute;ssea e o surgimento de deformidades no p&eacute; caracter&iacute;sticas da fase cr&oacute;nica<sup>22-24,26</sup>.</p>
    <p>Na fase cr&oacute;nica da NAC, o p&eacute; n&atilde;o apresenta sinais inflamat&oacute;rios, embora o edema permane&ccedil;a. Nesta fase existe deformidade do p&eacute; devido &agrave; diminui&ccedil;&atilde;o do arco plantar e ao equinismo causado pelo encurtamento do tend&atilde;o de Aquiles. Estas deformidades resultantes do atingimento osteoarticular e muscular originam locais de hiperpress&atilde;o e aumentam a probabilidade de ocorr&ecirc;ncia de &uacute;lceras e amputa&ccedil;&atilde;o, em simbiose com a isquemia caracter&iacute;stica desta fase<sup>15,22,27,28</sup>.</p></font>    <p>&nbsp;</p>    ]]></body>
<body><![CDATA[<p><b><font face="Verdana" size="2">CLASSIFICAÇÃO</font></b></p><font face="verdana" size="2">    <p>T&ecirc;m sido propostos diferentes sistemas de classifica&ccedil;&atilde;o para a NAC, sendo a classifica&ccedil;&atilde;o anat&oacute;mica de Sanders-Frykberg uma das mais populares. A NAC pode ser classificada segundo v&aacute;rios par&acirc;metros como por exemplo o estadio cl&iacute;nico, a localiza&ccedil;&atilde;o anat&oacute;mica e o estadio da hist&oacute;ria natural da doen&ccedil;a. As classifica&ccedil;&otilde;es existentes n&atilde;o t&ecirc;m valor progn&oacute;stico nem influenciam o tratamento4-6.</p></font>    <p><b><font face="Verdana" size="2">Classificação Clínica</font></b></p><font face="verdana" size="2">    <p>Clinicamente a NAC pode ser dividida no estadio agudo ou cr&oacute;nico. Na fase aguda ou activa o p&eacute; apresenta sinais inflamat&oacute;rios marcados (rubor, edema e calor) atingindo mais frequentemente o mediop&eacute;. A dor pode estar ausente, dependendo do grau de neuropatia. Neste estadio o p&eacute; n&atilde;o apresenta deformidades e a imagiologia &eacute; tipicamente normal<sup>5, 6</sup>.</p>
    <p>Por outro lado, na fase cr&oacute;nica ou inactiva, os sinais inflamat&oacute;rios locais regridem progressivamente, permanecendo, no entanto, o p&eacute; ruborizado mas com temperatura semelhante &agrave; do p&eacute; contralateral. &Eacute; nesta fase que o p&eacute; pode desenvolver deformidades caracter&iacute;sticas como colapso do arco plantar no mediop&eacute;, originando a &ldquo;deformidade rocker-bottom&rdquo; e a convexidade medial do mediop&eacute;5,6.</p></font>    <p><b><font face="Verdana" size="2">Classificação Anatómica</font></b></p><font face="verdana" size="2">    <p>V&aacute;rios autores propuseram classifica&ccedil;&otilde;es anat&oacute;micas da NAC de acordo com os padr&otilde;es de atingimento do p&eacute; e tornozelo, pois embora esta doen&ccedil;a tenha sido verificada em outras localiza&ccedil;&otilde;es corporais, no paciente diab&eacute;tico esta afeta quase exclusivamente o p&eacute; e o tornozelo3.</p>
    <p>Em 1991 Sanders e Frykberg propuseram a classifica&ccedil;&atilde;o anat&oacute;mica da NAC mais usada actualmente. Segundo esta classifica&ccedil;&atilde;o, a NAC pode ser dividida em cinco padr&otilde;es diferentes de acordo com as articula&ccedil;&otilde;es envolvidas<sup>3,5,7</sup> (<a name="topf2"></a><a href="#f2">Figura 2</a>).</p>    <p>&nbsp;</p><a name="f2"></a>     <p>    ]]></body>
<body><![CDATA[<center><img src="/img/revistas/rpot/v22n1/22n1a03f2.jpg" width="392" height="331" border="0" /></center></p>    
<p>&nbsp;</p>
    <p>O tipo I presente em 15% dos p&eacute;s com NAC, atinge as articula&ccedil;&otilde;es metatarsofal&acirc;ngicas e interfal&acirc;ngicas do p&eacute;. O tipo II, o mais comum, respons&aacute;vel por 40% dos p&eacute;s de Charcot, atinge as articula&ccedil;&otilde;es tarsometat&aacute;rsicas ou articula&ccedil;&atilde;o de Lisfranc. O segundo padr&atilde;o mais comum, o tipo III, presente em 30% da NAC, caracteriza-se por um atingimento das articula&ccedil;&otilde;es naviculocuneiforme, talonavicular e calcaneocub&oacute;ide. O padr&atilde;o tipo IV (10%) atinge as articula&ccedil;&otilde;es do tornozelo e a subtalar. Por &uacute;ltimo, o tipo V, presente em 5%, afecta a regi&atilde;o do calc&acirc;neo. Os tipos IV e V apresentam mau progn&oacute;stico devido &agrave; an&oacute;mala distribui&ccedil;&atilde;o da carga durante a marcha<sup>3,5,7</sup>.</p>
    <p>A classifica&ccedil;&atilde;o anat&oacute;mica de Sanders e Frykberg &eacute; apresentada na <a name="topt1"></a><a href="#t1">Tabela 1</a>.</p>    <p>&nbsp;</p><a name="t1"></a>     <p>    <center><img src="/img/revistas/rpot/v22n1/22n1a03t1.jpg" width="397" height="313" border="0" /></center></p>    
<p>&nbsp;</p>
    <p>Existe ainda uma classifica&ccedil;&atilde;o anat&oacute;mica mais simplista que caracteriza esta entidade em 3 tipos diferentes de acordo com a localiza&ccedil;&atilde;o do atingimento do p&eacute;: antep&eacute; (articula&ccedil;&otilde;es metatarsofal&acirc;ngicas e interfal&acirc;ngicas), mediop&eacute; (articula&ccedil;&otilde;es do tarso e tarsometat&aacute;rsicas) e retrop&eacute; (articula&ccedil;&atilde;o do tornozelo e calc&acirc;neo)10.</p>
    <p>Tamb&eacute;m Dounis classificou a NAC em tr&ecirc;s tipos distintos. O tipo I atinge o antep&eacute;, o tipo II o mediop&eacute; e o tipo III causa instabilidade severa ao atingir o retrop&eacute;. O tipo III subdivide-se em tipo IIIa( se atinge o tornozelo), tipo IIIb( se atinge a articula&ccedil;&atilde;o subtalar) e o tipo IIIc( se h&aacute; reabsor&ccedil;&atilde;o do talus e/ou calc&acirc;neo)10.</p>
    ]]></body>
<body><![CDATA[<p>A distribui&ccedil;&atilde;o da doen&ccedil;a pode tamb&eacute;m ser descrita usando a classifica&ccedil;&atilde;o de Brodsky (<a name="topt2"></a><a href="#t2">Tabela 2</a>). A NAC geralmente inicia-se na regi&atilde;o tarsometatarsal, apesar de poder ser vista na articula&ccedil;&atilde;o mediot&aacute;rsica, tornozelo ou nas fraturas patol&oacute;gicas do calc&acirc;neo7.</p>    <p>&nbsp;</p><a name="t2"></a>     <p>    <center><img src="/img/revistas/rpot/v22n1/22n1a03t2.jpg" width="346" height="464" border="0" /></center></p>    
<p>&nbsp;</p></font>    <p><b><font face="Verdana" size="2">Classificação de Roger</font></b></p><font face="verdana" size="2">    <p>Roger prop&ocirc;s uma classifica&ccedil;&atilde;o que considera a presen&ccedil;a de complica&ccedil;&otilde;es que podem ocorrer na NAC, como a presen&ccedil;a de deformidades, ulcera&ccedil;&atilde;o e osteomielite, e que poder&aacute; ser &uacute;til na previs&atilde;o da necessidade de amputa&ccedil;&atilde;o (<a name="topg1"></a><a href="#g1">Gr&aacute;fico 1</a>). Esta classifica&ccedil;&atilde;o &eacute; constitu&iacute;da por dois eixos (XY) e combina as caracter&iacute;sticas do exame cl&iacute;nico, radiogr&aacute;fico e anat&oacute;mico. O eixo X marca a localiza&ccedil;&atilde;o anat&oacute;mica do p&eacute; e tornozelo atingido e &eacute; dividido em tr&ecirc;s regi&otilde;es: antep&eacute;, mediop&eacute; e retrop&eacute;/tornozelo. O eixo Y descreve o grau de complica&ccedil;&atilde;o presente: A indica NAC aguda sem deformidade, B representa um p&eacute; de Charcot com deformidade; C representa um p&eacute; com deformidade e ulcera&ccedil;&atilde;o e D inclui osteomielite. Assim, movendo-se atrav&eacute;s do eixo X (envolvimento anat&oacute;mico) e / ou para baixo, o eixo Y (factores complicadores) a NAC torna-se " mais complicada " e portanto, h&aacute; maior risco de amputa&ccedil;&atilde;o<sup>7,23,27</sup>.</p>    <p>&nbsp;</p><a name="g1"></a>     <p>    <center><img src="/img/revistas/rpot/v22n1/22n1a03g1.jpg" width="388" height="297" border="0" /></center></p>    
]]></body>
<body><![CDATA[<p>&nbsp;</p></font>    <p><b><font face="Verdana" size="2">Classificação baseada na história natural da doença</font></b></p><font face="verdana" size="2">    <p>Em 1966 Eichenholtz prop&ocirc;s uma classifica&ccedil;&atilde;o que correlacionava os achados cl&iacute;nicos com os achados radiogr&aacute;ficos, baseando-se na apar&ecirc;ncia radiogr&aacute;fica da NAC e no seu curso fisiol&oacute;gico. A classifica&ccedil;&atilde;o de Eichenholtz divide a NAC em 3 fases distintas e lineares: desenvolvimento, coalesc&ecirc;ncia e consolida&ccedil;&atilde;o. No&nbsp; estadio I (desenvolvimento da doen&ccedil;a) existe eritema, edema e aumento da temperatura; a radiografia do p&eacute; &eacute; normal, mas pode existir debris &oacute;sseos nas articula&ccedil;&otilde;es, fragmenta&ccedil;&atilde;o &oacute;ssea subcondral, subluxa&ccedil;&atilde;o ou fratura4-6. No estadio II ocorre a diminui&ccedil;&atilde;o gradual dos sinais inflamat&oacute;rios e a doen&ccedil;a torna-se mais evidente ao n&iacute;vel radiol&oacute;gico (ocorre reabsor&ccedil;&atilde;o dos debris &oacute;sseos com nova forma&ccedil;&atilde;o &oacute;ssea e esclerose). No estadio III (consolida&ccedil;&atilde;o da doen&ccedil;a), n&atilde;o h&aacute; sinais inflamat&oacute;rios e radiograficamente verifica-se remodela&ccedil;&atilde;o dos ossos e articula&ccedil;&otilde;es afectados. &Eacute; durante esta fase que as deformidades podem alterar a arquitetura do p&eacute;, predispondo &agrave; ulcera&ccedil;&atilde;o6.</p>
    <p>Em 1990 foi proposta uma adapta&ccedil;&atilde;o &agrave; classifica&ccedil;&atilde;o de Eichenholtz a qual inclu&iacute;a uma fase anterior &agrave; fase de desenvolvimento, o denominado Estadio 0 ou fase inflamat&oacute;ria (<a name="topt3"></a><a href="#t3">Tabela 3</a>). Segundo esta classifica&ccedil;&atilde;o, a NAC inicia-se com um trauma n&atilde;o percept&iacute;vel decorrente da neuropatia, originando um p&eacute; com sinais inflamat&oacute;rios, muitas vezes confundido com celulite, gota ou TVP. Esta fase pode preceder o surgimento das altera&ccedil;&otilde;es radiogr&aacute;ficas em at&eacute; um ano e pode ser detectada atrav&eacute;s da RMN. As les&otilde;es cumulativas podem evoluir para graves deformidades do p&eacute;, ulcera&ccedil;&atilde;o e amputa&ccedil;&atilde;o. A identifica&ccedil;&atilde;o desta fase prodr&oacute;mica pode impedir a progress&atilde;o para as &uacute;ltimas fases da NAC prevenindo mais deformidades e complica&ccedil;&otilde;es<sup>4, 5, 29, 30</sup>.</p>    <p>&nbsp;</p><a name="t3"></a>     <p>    <center><img src="/img/revistas/rpot/v22n1/22n1a03t3.jpg" width="395" height="847" border="0" /></center></p>    
<p>&nbsp;</p></font>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">CONCLUSÃO</font></b></p><font face="verdana" size="2">    ]]></body>
<body><![CDATA[<p>A s&iacute;ndrome da NAC &eacute; uma complica&ccedil;&atilde;o importante resultante da diabetes e da neuropatia. O mecanismo exato da sua patog&eacute;nese ainda n&atilde;o est&aacute; esclarecido apesar de considerar-se, no presente, que quer a teoria neurotraum&aacute;tica quer a neurovascular poder&atilde;o ter um papel importante.</p>
    <p>Apesar de esta condi&ccedil;&atilde;o ser considerada uma das complica&ccedil;&otilde;es importantes da Diabetes, esta &eacute; identificada apenas numa pequena percentagem de Diab&eacute;ticos. Devido ao atraso no diagn&oacute;stico e tratamento da NAC esta progride para a forma&ccedil;&atilde;o de &uacute;lceras, aumentando assim o risco de amputa&ccedil;&atilde;o, da&iacute; a import&acirc;ncia de um diagn&oacute;stico e tratamento precoce.</p>
    <p>Embora v&aacute;rios autores tenham apresentado diferentes sistemas de classifica&ccedil;&atilde;o com alguma import&acirc;ncia cl&iacute;nica, estes n&atilde;o possuem valor progn&oacute;stico nem influenciam o tratamento.</p>
    <p>Trata-se de uma neuroartropatia com consequ&ecirc;ncias individuais e sociais importantes, que estando predominantemente associada &agrave; epidemia da Diabetes, merece especial aten&ccedil;&atilde;o a fim de diagnosticarmos e tratarmos precocemente esta complica&ccedil;&atilde;o decorrente deste grave problema de sa&uacute;de p&uacute;blica.</p></font>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">REFERÊNCIAS BIBLIOGRÁFICAS</font></b></p>    <!-- ref --><p><font face="verdana" size="2">1. Bowering Keith. Diabetic foot ulcers. Pathophysiology, assessment, and therapy. Canadian Family Physician - Le Médecin de famille canadien, FACP. 2001; 47 (2): 1007-1016</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000119&pid=S1646-2122201400010000300001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">2. Vella S, Cachia M. Charcot neuroarthropathy: pathogenesis, diagnosis and medical management. Malta Medical Journal. 2008; 20 (3): 13-19</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000120&pid=S1646-2122201400010000300002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">3. Rogers LC, Bevilacqua NJ. The diagnosis of Charcot foot. Clinics in Podiatric Medicine and Surgery. 2008; 25: 43-51</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000121&pid=S1646-2122201400010000300003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">4. Stanley J, Collier A. Charcot osteo-arthropathy. Current Orthopaedics. 2008; 22: 428-433</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000122&pid=S1646-2122201400010000300004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">5. Wukich D, Sungb W. Charcot arthropathy of the foot and ankle: modern concepts and management review. Journal of Diabetes and Its Complications. 2009; 23: 409-426</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000123&pid=S1646-2122201400010000300005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">6. Molines L, Darmon P, Raccah D. Charcot's Foot: Newest findings on its pathophysiology, diagnosis and treatment. Diabetes & Metabolism. 2010; 36: 251-255</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000124&pid=S1646-2122201400010000300006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">7. Varma A. Charcot Neuroarthropathy of the Foot and Ankle: A Review. The journal of foot and ankle surgery. 2013; 52: 740-749</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000125&pid=S1646-2122201400010000300007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">8. Rajbhandari SM, Jenkins RC, Davies C, Tesfaye S. Charcot neuroarthropathy in diabetes mellitus. Diabetologia. 2002; 45: 1085-1096</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000126&pid=S1646-2122201400010000300008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">9. Gouveri E, Papanas N. Charcot Osteoarthropathy in diabetes: A brief review with an emphasis on clinical practice. World Journal of Diabetes. 2011 May 15; 2 (5): 59-65</font></p>    <!-- ref --><p><font face="verdana" size="2">10. Papanas N, Maltezos E. Etiology, pathophysiology and classifications of the diabetic Charcot foot. Diabetic Foot & Ankle. 2013; 4: 208-272</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000128&pid=S1646-2122201400010000300010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">11. Petrova NL, Foster AV, Edmonds ME. Difference in presentation of charcot osteoarthropathy in type 1 compared with type 2 diabetes. Diabetes Care. 2004; 27: 1235-1236</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000129&pid=S1646-2122201400010000300011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">12. Fabrin J, Larsen K, Holstein PE. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care. 2000; 23: 796-800</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000130&pid=S1646-2122201400010000300012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">13. Rogers L. The Charcot Foot in Diabetes. Diabetes Care. 2011; 34: 2123-2129</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000131&pid=S1646-2122201400010000300013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">15. Hartemann-Heurtier A, Ha Van G, Grimaldi A. The Charcot foot. The Lancet. 2002; 360: 1776-1779</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000132&pid=S1646-2122201400010000300014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">16. Jeffcoate WJ. Charcot neuro-osteoarthropathy. Diabetes Metabolic Research Review. 2008; 24 (1): 2-5</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000133&pid=S1646-2122201400010000300015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">17. Jeffcoate W, Lima J, Nobrega L. The Charcot foot. Diabetic Medical. 2000; 17: 253-258</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000134&pid=S1646-2122201400010000300016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">18. Mascarenhas JV, Jude EB. Pathogenesis and medical management of diabetic Charcot neuroarthropathy. Medical Clinic North American. 2013; 97 (5): 857-872</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000135&pid=S1646-2122201400010000300017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">19. Jeffcoate WJ, Game FL, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet. 2005; 366: 2058-2061</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000136&pid=S1646-2122201400010000300018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">20. Jeffcoate WJ. Theories concerning the pathogenesis of the acute Charcot foot suggest future therapy. Current Diabetes Reports. 2005; 5: 430-435</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000137&pid=S1646-2122201400010000300019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">21. Petrova NL, Edmonds ME. Charcot neuro-osteoarthropathy current standards. Diabetes Metabolic Research Review. 2008; 24 (1): 58-61</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000138&pid=S1646-2122201400010000300020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">22. Papanas N, Maltezos E. Etiology, pathophysiology and classifications of the diabetic Charcot foot. Diabet Foot Ankle. 2013; 21 (4)</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000139&pid=S1646-2122201400010000300021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">23. Christensen TM. Charcot's arthropathy (article in danish). Ugeskr Laeger. 2008; 170 (33): 2440-2445</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000140&pid=S1646-2122201400010000300022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">24. Gastaldi G, Ruiz J, Borens O.. Charcot osteoarthropathy: don't miss it! (article in french). Revue Médicale Suisse. 2013; 9 (389): 1212-1220</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000141&pid=S1646-2122201400010000300023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">25. Schlossbauer T, Mioc T, Sommerey S, Kessler SB, Reiser MF, Pfeifer KJ. Magnetic resonance imaging in early stage charcot arthropathy: correlation of imaging findings and clinical symptoms. European Journal of Medical Research. 2008 Sep 22; 13 (9): 409-414</font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="verdana" size="2">26. Rogers L, Frykberg R. The charcot Foot. Medical Clinics of North America. 2013; 97 (5): 847-856</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000143&pid=S1646-2122201400010000300025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">27. Ferreira R, Gonçalez D, Fonseca Filho J, Costa M, Lima Santin R. Artropatia de Charcot do mediopé no paciente diabético: complicação de uma doença epidêmica. Revista Brasileira de Ortopedia. 2012; 47 (5): 616-625</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000144&pid=S1646-2122201400010000300026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">28. Rathur Haris M, Boulton Andrew JM. The diabetic foot. Clinics in Dermatology. 2007; 25 (1): 109-120</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000145&pid=S1646-2122201400010000300027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p><font face="verdana" size="2">29. Dissanayake S, Bowling F, Jude E. O Pé de Charcot Diabético. Diabetes. 2012; 8 (3): 191-194</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=000146&pid=S1646-2122201400010000300028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><p><font face="verdana" size="2">30. Morrison WB, Shortt CP, Ting AYI. Imaging of the Charcot foot. In RG Frykberg, editors. The Diabetic Charcot Foot: Principles and Management. Brooklandville: Data Trace Publishing; 2010. p. 65-84.</font></p>    <p>&nbsp;</p>    <p><b><font face="Verdana" size="2">Conflito de interesse: </font></b></p><font face="verdana" size="2">    <p>Nada a declarar.</p></font>    <p>&nbsp;</p><a name="c"></a>    <p><b><font face="Verdana" size="2"><a href="#topc">Endereço para correspondência</a></font></b></p>    ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Ana Pinheiro    <br>Unidade Local de Saúde do Alto Minho - Viana do Castelo    <br>Estrada de Santa Luzia    <br>4901-858, Viana do Castelo    <br>Portugal    <br><a href="mailto:ana.alexandra.pinheiro@gmail.com">ana.alexandra.pinheiro@gmail.com</a></font></p>    <p>&nbsp;</p>    <p><font face="verdana" size="2"><b>Data de Submissão: </b> 2013-11-21</font></p>    <p><font face="verdana" size="2"><b>Data de Revisão: </b> 2014-03-03</font></p>    <p><font face="verdana" size="2"><b>Data de Aceitação: </b> 2014-03-03</font></p>    ]]></body>
<body><![CDATA[ ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bowering]]></surname>
<given-names><![CDATA[Keith]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diabetic foot ulcers: Pathophysiology assessment and therapy]]></article-title>
<source><![CDATA[Canadian Family Physician - Le Médecin de famille canadien, FACP]]></source>
<year>2001</year>
<volume>47</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1007-1016</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vella]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cachia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Charcot neuroarthropathy: pathogenesis diagnosis and medical management]]></article-title>
<source><![CDATA[Malta Medical Journal]]></source>
<year>2008</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>13-19</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Bevilacqua]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The diagnosis of Charcot foot]]></article-title>
<source><![CDATA[Clinics in Podiatric Medicine and Surgery]]></source>
<year>2008</year>
<volume>25</volume>
<page-range>43-51</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stanley]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Collier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Charcot osteo-arthropathy]]></article-title>
<source><![CDATA[Current Orthopaedics]]></source>
<year>2008</year>
<volume>22</volume>
<page-range>428-433</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wukich]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sungb]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Charcot arthropathy of the foot and ankle: modern concepts and management review]]></article-title>
<source><![CDATA[Journal of Diabetes and Its Complications]]></source>
<year>2009</year>
<volume>23</volume>
<page-range>409-426</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molines]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Darmon]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Raccah]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Charcot's Foot: Newest findings on its pathophysiology diagnosis and treatment]]></article-title>
<source><![CDATA[Diabetes & Metabolism]]></source>
<year>2010</year>
<volume>36</volume>
<page-range>251-255</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Varma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Charcot Neuroarthropathy of the Foot and Ankle: A Review]]></article-title>
<source><![CDATA[The journal of foot and ankle surgery]]></source>
<year>2013</year>
<volume>52</volume>
<page-range>740-749</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajbhandari]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Jenkins]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tesfaye]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Charcot neuroarthropathy in diabetes mellitus]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>2002</year>
<volume>45</volume>
<page-range>1085-1096</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gouveri]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Papanas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Charcot Osteoarthropathy in diabetes: A brief review with an emphasis on clinical practice]]></article-title>
<source><![CDATA[World Journal of Diabetes]]></source>
<year>15/0</year>
<month>5/</month>
<day>20</day>
<volume>2</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>59-65</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papanas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maltezos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Etiology, pathophysiology and classifications of the diabetic Charcot foot]]></article-title>
<source><![CDATA[Diabetic Foot & Ankle]]></source>
<year>2013</year>
<volume>4</volume>
<page-range>208-272</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petrova]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Foster]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Edmonds]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Difference in presentation of charcot osteoarthropathy in type 1 compared with type 2 diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2004</year>
<volume>27</volume>
<page-range>1235-1236</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fabrin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Holstein]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Long-term follow-up in diabetic Charcot feet with spontaneous onset]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2000</year>
<volume>23</volume>
<page-range>796-800</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Charcot Foot in Diabetes]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2011</year>
<volume>34</volume>
<page-range>2123-2129</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartemann-Heurtier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ha Van]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grimaldi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Charcot foot]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2002</year>
<volume>360</volume>
<page-range>1776-1779</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeffcoate]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Charcot neuro-osteoarthropathy]]></article-title>
<source><![CDATA[Diabetes Metabolic Research Review]]></source>
<year>2008</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2-5</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeffcoate]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nobrega]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Charcot foot]]></article-title>
<source><![CDATA[Diabetic Medical]]></source>
<year>2000</year>
<volume>17</volume>
<page-range>253-258</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mascarenhas]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Jude]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pathogenesis and medical management of diabetic Charcot neuroarthropathy]]></article-title>
<source><![CDATA[Medical Clinic North American]]></source>
<year>2013</year>
<volume>97</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>857-872</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeffcoate]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Game]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Cavanagh]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<page-range>2058-2061</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeffcoate]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Theories concerning the pathogenesis of the acute Charcot foot suggest future therapy]]></article-title>
<source><![CDATA[Current Diabetes Reports]]></source>
<year>2005</year>
<volume>5</volume>
<page-range>430-435</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petrova]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Edmonds]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Charcot neuro-osteoarthropathy current standards]]></article-title>
<source><![CDATA[Diabetes Metabolic Research Review]]></source>
<year>2008</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58-61</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papanas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maltezos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Etiology, pathophysiology and classifications of the diabetic Charcot foot]]></article-title>
<source><![CDATA[Diabet Foot Ankle]]></source>
<year>2013</year>
<volume>21</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Charcot's arthropathy (article in danish)]]></article-title>
<source><![CDATA[Ugeskr Laeger]]></source>
<year>2008</year>
<volume>170</volume>
<numero>33</numero>
<issue>33</issue>
<page-range>2440-2445</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gastaldi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Borens]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang="fr"><![CDATA[Charcot osteoarthropathy: don't miss it (article in french)]]></article-title>
<source><![CDATA[Revue Médicale Suisse]]></source>
<year>2013</year>
<volume>9</volume>
<numero>389</numero>
<issue>389</issue>
<page-range>1212-1220</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schlossbauer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mioc]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sommerey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kessler]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Reiser]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeifer]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Magnetic resonance imaging in early stage charcot arthropathy: correlation of imaging findings and clinical symptoms]]></article-title>
<source><![CDATA[European Journal of Medical Research]]></source>
<year>22/0</year>
<month>9/</month>
<day>20</day>
<volume>13</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>409-414</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Frykberg]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The charcot Foot]]></article-title>
<source><![CDATA[Medical Clinics of North America]]></source>
<year>2013</year>
<volume>97</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>847-856</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gonçalez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca Filho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lima Santin]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Artropatia de Charcot do mediopé no paciente diabético: complicação de uma doença epidêmica]]></article-title>
<source><![CDATA[Revista Brasileira de Ortopedia]]></source>
<year>2012</year>
<volume>47</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>616-625</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rathur]]></surname>
<given-names><![CDATA[Haris M]]></given-names>
</name>
<name>
<surname><![CDATA[Boulton]]></surname>
<given-names><![CDATA[Andrew JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The diabetic foot]]></article-title>
<source><![CDATA[Clinics in Dermatology]]></source>
<year>2007</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>109-120</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dissanayake]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bowling]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jude]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[O Pé de Charcot Diabético]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2012</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>191-194</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>30</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Shortt]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Ting]]></surname>
<given-names><![CDATA[AYI]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Imaging of the Charcot foot]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[RG]]></surname>
<given-names><![CDATA[Frykberg]]></given-names>
</name>
</person-group>
<source><![CDATA[The Diabetic Charcot Foot: Principles and Management]]></source>
<year>2010</year>
<page-range>65-84</page-range><publisher-loc><![CDATA[Brooklandville ]]></publisher-loc>
<publisher-name><![CDATA[Data Trace Publishing]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
